As recognized leaders in next-generation sequencing (NGS), Illumina has a portfolio of cutting-edge genomic sequencing systems and services that can fuel all phases of your oncology discovery and development pipeline. We are uniquely positioned to support you with the largest install base of NGS instrumentation in the world.1 In fact, ~90% of all sequencing data ever produced has been generated using Illumina technologies.* It’s a record of experience you can confidently trust as you choose a partner to help accelerate your development of cancer companion diagnostics (CDx).
We offer comprehensive NGS solutions to streamline and transform the tumor-profiling paradigm from a series of single-gene tests to a multi-analyte approach that can capture a more thorough picture of a tumor’s genomic landscape. Such knowledge may help identify candidates for clinical trials faster and more economically. We are partnering with leading pharmaceutical and biotechnology companies and the oncology community to develop companion diagnostics for best-in-class therapeutics. We are focusing on a comprehensive set of currently actionable and emerging biomarkers relevant to cancer drug development.Learn More
Some cancer research discoveries using NGS have become the basis for companion diagnostics and laboratory developed tests (LDT) now in use in molecular diagnostic laboratories worldwide. These laboratories are now faced with an evolving landscape of regulations and reimbursement strategies for NGS oncology testing.
We spoke with several key opinion leaders about the ongoing challenges and potential of NGS in oncology testing.Read Interview
* Data on file derived from 2013 study.